Project Grant H8E37852

This $251,493 federal Project Grant award from the National Science Foundation's (NSF) Engineering program (CFDA 47.041) supports research to develop optimized pooled testing strategies for efficient prevalence tracking and accurate COVID-19 infection diagnosis. The key products and services to be delivered include: Designing effective sampling and testing algorithms to estimate community prevalence under resource constraints (Thrust 1); developing optimized pooling and decoding algorithms for...

This federal Cooperative Agreement award, totaling $5,100,000 and provided by the Centers for Disease Control and Prevention (CDC) Epidemiology and Laboratory Capacity for Infectious Diseases (CFDA 93.323) program, aims to build capacity for state, tribal, local, and territorial applied epidemiologists. The primary awardee, the Council of State and Territorial Epidemiologists, Inc. (CSTE), will provide critical capacity building assistance and technical expertise to enhance infectious disease...

Numentus Technologies Inc. received a $303,685 Project Grant award from the National Science Foundation on February 15, 2021 to develop rapid planar PCR technology for COVID-19 testing. The award was made under the NSF's Engineering program (CFDA 47.041) to support innovation and excellence in engineering research. Through this funding, Numentus will work to advance the development of planar PCR, a technology that enables highly sensitive COVID-19 detection on a single integrated testing...

The Centers for Disease Control and Prevention (CDC) awarded a $918,351 Cooperative Agreement under the Epidemiology and Laboratory Capacity for Infectious Diseases (CFDA 93.323) program to the Indiana Department of Health. This 5-year award, effective August 1, 2024, aims to strengthen Indiana's public health infrastructure for detecting, responding to, preventing, and controlling infectious diseases. Key focus areas include enhancing epidemiological surveillance, laboratory testing...

This $505,746 Cooperative Agreement, awarded by the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (CFDA 93.323) program, supports the FSM Department of Health and Social Affairs in enhancing public health infrastructure for detecting, responding to, preventing, and controlling infectious diseases across the Federated States of Micronesia. Key activities to be carried out under this 5-year award include: Strengthening...

The City of New York, through its Department of Health and Mental Hygiene (Health Dept), has been awarded a $3,996,611.00 Cooperative Agreement by the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323). This 5-year award, effective August 1, 2024, will support the Health Dept's efforts to enhance public health infrastructure for detecting, responding to, preventing, and controlling infectious...

The Utah Department of Health and Human Services (UDHHS) was awarded a $1,167,075 Cooperative Agreement by the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323). The funding will support a 5-year project from August 1, 2024 to July 31, 2029 to enhance Utah's public health infrastructure and capacity for detecting, responding to, preventing, and controlling infectious diseases. Key activities to be...

This Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323) will provide $1,499,856.00 to the University of Rochester from September 30, 2024 to September 29, 2027. The award supports activities to enhance public health infrastructure for detecting, responding to, preventing, and controlling infectious diseases. Key products and services to be delivered include...

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $40.4 million cooperative agreement to Exela Pharma Sciences, LLC (Exela) to expand industrial base capabilities for COVID-19 response. With a period of performance from May 2022 through May 2034, this cooperative agreement will support Exela under the Research on Chemical and Biological Defense program (CFDA 12.360). Through this cooperative agreement, Exela will further the government's...

The Task Force for Global Health, Inc. was awarded a $2,475,519 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) under the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) program (CFDA 93.323). The five-year award, effective from August 1, 2024 to July 31, 2029, supports the organization's efforts to strengthen public health infrastructure for detecting, responding to, preventing, and controlling infectious diseases globally. Key activities...